Visual Snow Syndrome: Diagnosis, Pathophysiology, and Treatment

Diagnostic criteria

The consensus criteria require all of the following:

Criterion A (core symptom)

Dynamic, continuous, tiny dots across the entire visual field persisting more than 3 months.

Criterion B

At least two of four additional visual symptom categories: (1) palinopsia (afterimages or trailing of moving objects, distinct from physiologic retinal afterimages); (2) enhanced entoptic phenomena (excessive floaters, prominent blue-field entoptic phenomenon, self-light of the eye, or spontaneous photopsia); (3) photophobia; and (4) nyctalopia (impaired night vision).

Criterion C

Symptoms are not consistent with typical migraine visual aura (no scintillating scotoma or zig-zag fortification lines).

Criterion D

Symptoms are not better explained by another disorder: normal ophthalmologic exam, no retinal pathology, no visual pathway lesion, no occipital epilepsy, and no relevant illicit drug intake.

The hallmark static is present with eyes open or closed and is typically more noticeable in dim light and against plain backgrounds; the dots may be black-and-white, transparent, or colored. In the original 78-patient cohort, 92% had at least three additional visual symptoms, underscoring that VSS is a symptom complex rather than an isolated finding. Neurological examination, ophthalmologic testing (acuity, color vision, OCT, perimetry), MRI, and EEG are characteristically normal in VSS; the workup is primarily to exclude mimics, and neuroimaging abnormalities described in the literature are research findings, not clinical diagnostic markers.

Differential diagnosis

VSS is a clinical diagnosis of exclusion, so its differential is essentially the list of conditions that can produce continuous pan-field "TV static" or the accompanying visual symptoms. The most important distinction is from migraine visual aura: migraine is comorbid in roughly 50 to 59% of VSS patients (with aura in about 27%), which historically caused conflation, but aura is short-lived, evolves over minutes, and precedes headache, whereas visual snow is continuous, pan-field, and does not fluctuate with the migraine cycle. VSS also fails to respond to standard migraine therapeutics. A separate entity, episodic visual snow, occurs transiently only during migraine attacks.

Screening every patient for recreational drug use is essential, since hallucinogen persisting perception disorder (HPPD) overlaps heavily with VSS and follows LSD, MDMA, cannabis, or synthetic cannabinoid exposure. A medication history is equally important: new-onset visual snow has been reported after several antidepressants, stimulants, and other agents, and stimulants, antidepressants, and antipsychotics may worsen existing symptoms. Historically, VSS has been misattributed to a psychogenic or functional disorder, a diagnosis to avoid without appropriate workup. Red flags pointing away from primary VSS include visual field defects, visual agnosia, color-vision difficulty, pulsatile tinnitus, and new onset later in life.

Pathophysiology

The prevailing model frames VSS as a disorder of widespread sensory processing: aberrant excitability and connectivity within visual pathways extending into attentional, salience, and limbic networks, rather than a focal lesion.

Cortical hyperexcitability and disinhibition

The most established theory. Visual evoked potentials show impaired habituation and prolonged N145 latency localizing dysfunction to the visual association cortex (lingual/fusiform region) rather than primary cortex; transcranial magnetic stimulation demonstrates a lower phosphene threshold; EEG and MEG show excitatory-inhibitory imbalance. Psychophysics point to increased neural gain rather than added neural noise, and these changes persist independent of migraine comorbidity.

Thalamocortical dysrhythmia

Implicates the lateral geniculate nucleus and pulvinar: excessive thalamic hyperpolarization disinhibits visual cortex and produces pathological low-frequency oscillatory entrainment, a model shared with tinnitus and migraine and consistent with their frequent co-occurrence. Altered pulvinar-lingual gyrus connectivity has been proposed to underlie photophobia.

Neuroimaging anchors the syndrome to extrastriate visual cortex

The landmark FDG-PET finding is hypermetabolism of the right lingual gyrus, with MR spectroscopy showing elevated lactate and a trend toward increased glutamate in the same region. Structural studies show gray matter volume increases in visual, motion (V5), insular, and cingulate regions that do not correlate with disease duration, suggesting a trait rather than a consequence, plus diffuse white matter alterations.

Neurotransmitter-level findings

Receptor-enriched functional connectivity analysis found reduced NMDA (glutamatergic) connectivity in cingulate cortex specific to VSS, and reduced serotonergic connectivity shared with migraine with aura, positioning serotonergic dysfunction as a possible common link among VSS, migraine with aura, and HPPD. Reduced GABAergic inhibition is implicated indirectly. Familial clustering (roughly 2 to 10% with an affected first-degree relative) suggests a hereditary contribution, though no specific loci have been identified.

Epidemiology and prognosis

• Prevalence: The sole population-based study (UK, n=1,015) found 2.2% met full VSS criteria and 3.7% reported the symptom of visual snow. The condition is likely clinically underrecognized.
• Demographics and onset: Median age at onset is about 24.5 years, with a slight female predominance; notably, about 40% report having had symptoms for as long as they can remember, indicating childhood onset in a large minority. Onset may be lifelong, abrupt, gradual, or stepwise, and is sometimes attributed to a migraine attack, concussion, infection, or medication.
• Comorbidities: Migraine (about 50 to 72%, especially with aura), daily tinnitus (52 to 75%), and mood and anxiety disorders (lifetime depression about 41%, anxiety about 45%) are highly prevalent, along with dizziness, fibromyalgia, and depersonalization/derealization, supporting the concept of VSS within a broader spectrum of perceptual disorders sharing migraine as a risk factor.
• Natural history: Once established, VSS is generally chronic and non-progressive; symptoms fluctuate but full remission is uncommon, making validation and expectation-setting central to care.

Treatment

There is no approved or reliably effective pharmacotherapy, and most standard migraine and neuropathic agents fail. Lamotrigine has the best (still limited) evidence base among medications, with a minority of patients reporting meaningful improvement. Blue-yellow color-tinted lenses, including FL-41 filters, reduce symptom intensity and visual stress for many patients and are a reasonable first-line, low-risk intervention. New or worsening visual snow has been reported with several psychotropics, so medication review and cautious titration matter. Because migraine, tinnitus, anxiety, and depression drive much of the disability, treating comorbidities, plus reassurance that the syndrome is real, non-degenerative, and typically non-progressive, is often the most valuable intervention. Ongoing research into cortical neuromodulation offers future possibilities.

References

1. Schankin CJ, Maniyar FH, Digre KB, Goadsby PJ. 'Visual snow': a disorder distinct from persistent migraine aura. Brain. 2014;137(5):1419-1428. doi.org/10.1093/brain/awu050
2. Stern M, Robertson CE. Visual snow syndrome: update on clinical characteristics and pathophysiology. Current Opinion in Neurology. 2024.
3. van Dongen RM, Waaijer LC, Onderwater GLJ, Ferrari MD, Terwindt GM. Treatment effects and comorbid diseases in 58 patients with visual snow. Neurology. 2019;93(4):e398-e403. doi.org/10.1212/WNL.0000000000007825
4. Kondziella D, Olsen MH, Dreier JP. Prevalence of visual snow syndrome in the UK. European Journal of Neurology. 2020;27(5):764-772. doi.org/10.1111/ene.14150
5. Puledda F, Schankin C, Goadsby PJ. Visual snow syndrome: a clinical and phenotypical description of 1,100 cases. Neurology. 2020;94(6):e564-e574. doi.org/10.1212/WNL.0000000000008909
6. Puledda F, et al. Neurotransmitter-level functional connectivity in visual snow syndrome: reduced NMDA and serotonergic connectivity. 2023.
7. Eren O, et al. Cortical hyperexcitability in visual snow syndrome: evidence from visual evoked potentials and transcranial magnetic stimulation. 2018.
8. Fraser CL. Visual snow: an update on clinical and investigative findings. Current Opinion in Ophthalmology. 2022.
9. Klein A, Schankin CJ. Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: a narrative review. Headache. 2021.
10. Mehta DG, et al. Visual snow syndrome: a review of diagnosis, pathophysiology, and treatment. Neurology: Clinical Practice. 2021.
11. Ford H, et al. Hallucinogen persisting perception disorder and visual snow syndrome: overlapping entities. 2022.
12. Metzler AI, Robertson CE. Visual snow syndrome: proposed criteria, clinical implications, and pathophysiology. Current Neurology and Neuroscience Reports. 2018;18(8):52. doi.org/10.1007/s11910-018-0854-2